AM-694 Stats & Data

AM-694 is an extremely potent CB1-preferring agonist originally developed for PET imaging; sub-milligram accuracy is mandatory. Consider volumetric dosing to mitigate measurement error with such potency. Forum-era reports describe a calm, plateauing high in some, but acute anxiety, tachycardia, confusion, and brief psychotic symptoms in others; several reports of short hospitalisations occurred shortly after its appearance in 2010. Severe and unpredictable adverse effects (e.g., agitation, seizures, loss of consciousness, acute kidney injury) are well documented for the synthetic cannabinoid class; AM-694’s safety profile is poorly characterised. Avoid unknown ‘herbal blend’ products and homemade sprays—batch-to-batch variability and mislabeling were common in early markets. Combining with CNS depressants (opioids, alcohol, benzodiazepines, GHB) increases risk of dangerous respiratory/CNS suppression; with stimulants it increases cardiovascular strain and panic risk. Start with very low test doses, wait full onset (especially oral), and avoid redosing loops—rapid tolerance and compulsion to redose are typical with potent synthetics. Prefer controlled vaporisation over direct flame to limit unknown pyrolysis byproducts; do not heat solutions on coils to charring. Reagent kits are generally unreliable for identifying synthetic cannabinoids; only lab-grade analysis can confirm identity/potency. Long-term safety is unknown; avoid frequent use and consider extra caution if you have cardiovascular, seizure, or psychiatric risk factors.